ClinicalTrials.gg
CompletedNCT03986320Updated Sep 30, 2026

Evaluation of the Effectiveness and Safety of Keeogo™ Dermoskeleton in Subjects With Mobility Impairments Due to Stroke

An interventional study of Keeogo™ Dermoskeleton in Stroke, Ischemic, Stroke Hemorrhagic and Stroke, sponsored by B-Temia, Inc.. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by B-Temia, Inc. · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was Mar 2020, 6 years 8 months ago, and no results have been posted to the registry.
Updated Sep 30, 2026Now CompletedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Enrollment
192nd of 364
60 · median 65
Started
2019
with 24 others
No phase
183 of 480
51 open now
Registered
253rd of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 192nd largest by enrollment of the 364 interventional ones that give a count, is one of 25 that started in 2019, is one of 183 with no phase, and was the 253rd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the Keeogo™ Dermoskeleton in subjects with hemiparesis due to ischemic or hemorrhagic stroke.

Read the detailed description

Stroke affects thousands of individuals annually, leading to considerable physical impairment and functional disability. Gait is one of the most important activities of daily living affected in this patient population. Recent technological developments in passively powered dermoskeleton can create powerful adjunctive tools for rehabilitation and potentially accelerate functional recovery. Here, the investigators present the development and evaluation of a lower limb dermoskeleton, namely Keeogo™ (B-Temia), for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.

Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves.

03

Conditions studied

  • Stroke, Ischemic
  • Stroke Hemorrhagic
  • Stroke
  • Hemiparesis
  • Cerebral Vascular Accident

Keywords

  • Keeogo™
  • Dermoskeleton
  • Powered dermoskeleton
  • Lower limb dermoskeleton
  • Assistive exoskeleton
  • Orthotic dermoskeleton
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in this study, an individual must meet all of the following criteria:

  • Provide signed and dated form;
  • Willing to comply with all study procedures and be available for the duration of the study [2-3 days per week, 3-5 consecutive weeks];
  • Adults 18 years of age and older;
  • Confirmed Cerebrovascular Accident (CVA) with hemiparesis;
  • Stable stroke (≥ 6 months post-incident)
  • Sufficient cognition to follow simple instructions and understand the content and purpose of the study ( > 20);
  • Capable of standing and walking independently for an extended period of time (MMT

    • 3 hip flexors and extensors, and ≥ 2 knee flexors and extensors with BBS ≥ 45);
  • Presence of any gait deficit, as defined by one or more of the following clinical observations:

    • Hip hike
    • Hip circumduction
    • Knee spasticity (MAS 2 to 3) as per Modified Ashworth Scale (MAS)
    • Mid-foot striking (aka 'flat foot landing')
    • Poor foot clearance (toe/foot drop or foot drag)
    • Narrow steps (\< 1 shoe-width or \< 8 cm)
  • Manual Muscle Test (MMT) of 4/5 for the unaffected upper extremity;
  • Able to sit on a bench for more than 5 minutes;
  • Is physically and mentally compatible with device to demonstrate ability to safely activate the Keeogo™ user interface;
  • Able to understand and follow instructions with assistance if needed.

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Legally blind
  • Pregnant, lactating, or postpartum sacroiliac joint recovery is ongoing (recent childbirth, not yet cleared for vigorous exercise)
  • Skin condition that contraindicates use of orthotics or support braces
  • Recent (\<6 mo) lower-body hospitalizations or active treatments due to a joint, muscle, bone, nerve or vascular injury or condition
  • Scheduled for major surgery within next 4 months
  • Lower-extremity amputation above or below the knee
  • Have uncontrolled hypertension
  • Recent (\<1 year) heart attack
  • Have uncontrolled diabetes
  • Diagnosed with other health condition(s) that affect mobility and balance; ; peripheral arterial disease; vestibular disorders; cerebellar disease; cerebral palsy; muscular dystrophy spinal cord injury; other brain injury aside from the reported CVA;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Keeogo™ Dermoskeleton

    Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves.

    Device: Keeogo™ Dermoskeleton

Interventions

  • DeviceKeeogo™ Dermoskeleton

    This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.

06

What researchers measure

Primary outcomes

  1. Incidence of device-related adverse events [Safety]

    Safety will be evaluated on the basis of the number of device-related serious adverse events reported for subjects during their participation in the study.

    Time frame: Duration of study participation for each subject, estimated 3-5 weeks

Secondary outcomes

  1. Incidence of device malfunctions during study procedures [Device Reliability]

    Device reliability will be evaluated on the basis of the number of device malfunctions reported by research study staff for the duration of study procedures at each study site.

    Time frame: Duration of study completion for each site, estimated 3-5 weeks

  2. Incidence of injury to Physical Therapist (PT) caused by device [PT safety]

    PT safety will be evaluated on the basis of the number of serious device-related injuries reported by study physical therapists for the duration of study procedures at each study site.

    Time frame: Duration of study completion for each site, estimated 3-5 weeks

  3. Device, Effectiveness

    Clinician and Patient Reported Outcomes (surveys) will be used to assess the effectiveness of the device in assisting gait. The surveys will rate subject performance in walking based on clinician observed deviations and subject perception of mobility limitation due to the stroke. * Device effectiveness will be measured based on statistical analysis of the survey data between conditions (baseline compared to device-use) Ratings by the surveys will be validated using instrumented walkway and image data collected during walking.

    Time frame: Duration of study participation for each subject, estimated 3-5 weeks

Other outcomes

  1. 30-Second Chair Stand Test

    Subjects sit in the middle of chair and place hands on opposite shoulder crossed at wrists. Keeping feet flat on floor, back straight, arms against chest, subjects rise to full standing position when told "go" followed by sit down, the start position. This movement is repeated for as many times as possible for 30 seconds. Additionally, the test is repeated for a total of 5 cycles with short rest (≤ 90 seconds) between sets. Patient and Clinician reported outcomes are assessed for this measure via a sit-to-stand-to-sit question on the survey given for the secondary effectiveness endpoint.

    Time frame: Duration of study completion for each site, estimated 3-5 weeks

  2. Timed Stair Test

    Subjects start with both feet on the bottom landing then ascend and descend a set number of stairs as quickly as possible in a safe manner using a rail only if needed. Time is recorded from ascent through descent. Patient and Clinician reported outcomes are assessed for this measure via a stair ascent/descent question on the survey given for the secondary effectiveness endpoint.

    Time frame: Duration of study completion for each site, estimated 3-5 weeks

  3. Patient and Clinician Reported Outcomes (surveys)

    Questionnaires provide patient and clinician-centric view of treatment of gait deficit.

    Time frame: Duration of study completion for each site, estimated 3-5 weeks

07

Study locations

4 sites
  • Shirley Ryan Ability Lab (SRA)
    Chicago, Illinois 60611, United States
  • Human Performance and Engineering Research (HPER)
    West Orange, New Jersey 07052, United States
  • James J Peters VA Medical Center - Center for the Medical Consequences of Spinal Cord Injury
    The Bronx, New York 10468, United States
  • Assistive Technology Clinic (ATC)
    Toronto, Ontario M6A 2E1, Canada
08

References and documents

Publications

  • Buesing C, Fisch G, O'Donnell M, Shahidi I, Thomas L, Mummidisetty CK, Williams KJ, Takahashi H, Rymer WZ, Jayaraman A. Effects of a wearable exoskeleton stride management assist system (SMA(R)) on spatiotemporal gait characteristics in individuals after stroke: a randomized controlled trial. J Neuroeng Rehabil. 2015 Aug 20;12:69. doi: 10.1186/s12984-015-0062-0. PubMed 26289955 ↗
  • Xu J, Murphy SL, Kochanek KD, Bastian B, Arias E. Deaths: Final Data for 2016. Natl Vital Stat Rep. 2018 Jul;67(5):1-76. PubMed 30248015 ↗
  • He Y, Eguren D, Luu TP, Contreras-Vidal JL. Risk management and regulations for lower limb medical exoskeletons: a review. Med Devices (Auckl). 2017 May 9;10:89-107. doi: 10.2147/MDER.S107134. eCollection 2017. PubMed 28533700 ↗
  • Lee SH, Lee HJ, Chang WH, Choi BO, Lee J, Kim J, Ryu GH, Kim YH. Gait performance and foot pressure distribution during wearable robot-assisted gait in elderly adults. J Neuroeng Rehabil. 2017 Nov 28;14(1):123. doi: 10.1186/s12984-017-0333-z. PubMed 29183379 ↗
  • Morawietz C, Moffat F. Effects of locomotor training after incomplete spinal cord injury: a systematic review. Arch Phys Med Rehabil. 2013 Nov;94(11):2297-308. doi: 10.1016/j.apmr.2013.06.023. Epub 2013 Jul 9. PubMed 23850614 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Mar 2020, 7 months.

Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 7 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2019
First posted
Jun 14, 2019
StartActual
Jul 22, 2019
Primary completionActual
Mar 20, 2020
CompletionActual
Sep 10, 2020
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Sep 30, 2026
Sites
1 site added, 1 site removed
Show site
  • James J Peters VA Medical Center - Center for the Medical Consequences of Spinal Cord Injury · The Bronx, United States
Show 1 removed
  • James J Peters VA Medical Center - Center for the Medical Consequences of Spinal Cord Injury · Bronx, United States
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Status unknown→Completed
    1 site added, 1 site removed
    Show site
    • James J Peters VA Medical Center - Center for the Medical Consequences of Spinal Cord Injury · The Bronx, United States
    Show 1 removed
    • James J Peters VA Medical Center - Center for the Medical Consequences of Spinal Cord Injury · Bronx, United States
    + 4 other changes: verification date, date precision, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03986320
Lead sponsor
B-Temia, Inc.
Responsible party
Sponsor
First posted
Jun 14, 2019
Start date
Jul 22, 2019
Primary completion
Mar 20, 2020
Completion
Sep 10, 2020
Last update
Sep 30, 2026

Study contacts

Arun Jayaraman, PT, PhD.
principal investigator · Shirley Ryan Ability Lab (SRA)

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion